Effectiveness of retigabine against levobupivacaine-induced central nervous system toxicity: a prospective,

Yanxin Cheng1, Hong Li2, Jun Li3

  • 1Pain Medicine Center, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Journal of Anesthesia
|August 26, 2015
PubMed
Abstract

Insights

Retigabine effectively terminated levobupivacaine-induced seizures in rabbits by activating KCNQ2/3 channels. This suggests KCNQ2/3 channel openers may treat local anesthetic-induced central nervous system toxicity.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Channelopathies

Background:

  • KCNQ2/3 channels are crucial for regulating neuronal excitability.
  • Agents that decrease KCNQ2/3 current amplitude are proconvulsant, while enhancers are anticonvulsant.
  • Levobupivacaine blocks KCNQ2/3 channels, increasing neuronal excitation, whereas retigabine reopens them, reducing overexcitation.

Purpose of the Study:

  • To investigate if retigabine can abolish seizures induced by the local anesthetic levobupivacaine.
  • To explore the role of KCNQ2/3 channels in local anesthetic-induced central nervous system toxicity.

Main Methods:

  • Twenty New Zealand rabbits were divided into two groups.
  • Levobupivacaine (0.5%) was infused intravenously until seizures occurred.
  • Retigabine (5 mg/kg) or saline was administered to terminate seizures, with continuous EEG and behavioral monitoring.

Main Results:

  • Retigabine effectively terminated both electrographic and behavioral seizures induced by levobupivacaine.
  • Following retigabine administration, rabbits exhibited drowsiness and EEG patterns shifted to delta waves.

Conclusions:

  • KCNQ2/3 channels are significantly involved in levobupivacaine-induced central nervous system toxicity.
  • KCNQ2/3 channel activators represent a potential therapeutic strategy for treating levobupivacaine-induced convulsions.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
969
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
723
Local Anesthetics: Adverse Effects01:12

Local Anesthetics: Adverse Effects

While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
994
Local Anesthetics: Differential Sensitivity of Nerve Fibers01:24

Local Anesthetics: Differential Sensitivity of Nerve Fibers

Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
1.7K